Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy Clinical Trial

Official title:

A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06209736
• Other study ID #: OMS906-C3G-001
• Status: Recruiting
• Phase: Phase 2
• Start date: March 1, 2024
• Est. completion date: April 2026

Study information

• Verified date: April 2024
• Source: Omeros Corporation
• Contact: Omeros Clinical Trial Information
• Phone: 206-676-5000
• Email: ctinfo[@]omeros.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Description:

This is a multicenter, open-label, uncontrolled, non-comparative, fixed-dose study. The primary objective is to assess safety and tolerability of OMS906 in patients with C3G or idiopathic ICGN, both complement-mediated disorders. Patients will receive 5 mg/kg administered as intravenous (IV) infusions at 4-week intervals. The study will enroll up to approximately 20 patients with C3G or ICGN. Safety will be evaluated in all patients and by disease cohort. Preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) will be evaluated by disease cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: April 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Male or female adults 18 years and older.

2. Competent to provide informed consent and has completed informed consent procedures.

3. Diagnosis of C3G, including dense deposit disease, or ICGN confirmed by biopsy within 36 months of screening.

4. Two 24-hour UPCR = 0.8 gm/gm with the 2 collections separated by 14 - 28 days.

5. GFR estimated by the CKD-EPI equation = 45 mL/min/1.73 m2.

6. Serum C3 concentration less than the lower limit of laboratory normal during screening.

7. Must be on stable maximally tolerated or allowed dose of ACE inhibitor or ARB for at least 90 days.

8. If receiving a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, must be on a stable dose for at least 90 days.

9. If receiving mycophenolate mofetil, a mineralocorticoid receptor antagonist, or a corticosteroid, must be on stable dose for at least 90 days.

10. Have current vaccination status for Neisseria meningitidis, Streptococcus pneumonia and Haemophilus influenza (where available) and agree to maintain vaccination throughout the study.

Patients who have not received these vaccinations at the time of screening may be vaccinated at any time prior to 2 weeks before the first study drug administration. Vaccine serotypes will be chosen by the local standard of care and serotype prevalence.

11. Female patients of child-bearing potential must have a negative highly sensitive pregnancy test at screening and prior to each dose of OMS906.

12. Females must use highly effective birth control* to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.

13. Males must use highly effective birth control* with a female partner to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.

Exclusion Criteria:

1. History of major organ transplant or hematopoietic stem cell/marrow transplant.

2. Have known congenital deficiency of any of complement factors C1q, C1r, C1s, C2 or C4.

3. Have rapidly progressing glomerulonephritis defined as a 50% or greater decline in the eGFR within 3 months with renal biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli.

4. Have renal biopsy findings showing interstitial fibrosis/tubular atrophy of more than 50%.

5. Immunodeficiency or treatment with immunosuppressive agents (except mycophenolate mofetil or corticosteroids at the prednisone equivalent of = 7.5 mg/day in patients with C3G only) within 90 days of screening.

6. Treatment with rituximab within 6 months of screening.

7. Resting blood pressure > 140/90 mmHg during screening.

8. History of any active malignancy within 5 years of screening except non-melanoma skin cancers.

9. History of monoclonal gammopathy of unknown significance or any autoimmune disorder.

10. Elevation of liver function tests, defined as total bilirubin > 2 × upper limit of normal (ULN), direct bilirubin > 1.5 × ULN, and elevated transaminases, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × ULN.

11. History of any severe hypersensitivity reactions to other monoclonal antibodies or excipients included in the OMS906 preparation.

12. Significant active bacterial or viral infection within the 2 weeks prior to screening including Covid-19 infection.

13. Use of any other complement inhibitor within 6 months prior to the screening visit.

14. Have human immunodeficiency virus, hepatitis B, or untreated hepatitis C infection.

15. Pregnant, planning to become pregnant, or nursing female patient.

16. Recent surgery requiring general anesthesia within the 2 weeks prior to screening or expected to have surgery requiring general anesthesia during the treatment period.

17. History of any significant medical, neurologic, or psychiatric disorder that in the opinion of the investigator would make the patient unsuitable for participation in the study.

18. Treatment with any investigational medicinal product or investigational device within 30 days (or within 5 × its half-life in days, whichever is the longer period) prior to screening, or participation in another concurrent clinical trial involving a therapeutic intervention. Participation in observational and/or registry studies is permitted.

19. Unable or unwilling to comply with the requirements of the study.

Related Conditions & MeSH terms

• C3 Glomerulopathy
• Glomerulonephritis

Intervention

Drug:
• OMS906 study drug
OMS906 study drug dose 5mg/kg IV administration at 4-week internals

Locations

Country	Name	City	State
Lithuania	Omeros Investigational Site	Kaunas
Lithuania	Omeros Investigational Site	Vilnius
New Zealand	Omeros Investigational Site	Auckland
Poland	Omeros Investigational Site	Lódz
Tunisia	Omeros Investigational Site	Monastir
Tunisia	Omeros Investigational Site	Tunis
Turkey	Omeros Investigational Site	Adana
Turkey	Omeros Investigational Site	Ankara
Turkey	Omeros Investigational Site	Denizli
Turkey	Omeros Investigational Site	Kayseri
United Kingdom	Omeros Investigational Site	Leicester
United Kingdom	Omeros Investigational Site	Newcastle Upon Tyne

Sponsors (1)

Lead Sponsor	Collaborator
Omeros Corporation

Countries where clinical trial is conducted

Lithuania,  New Zealand,  Poland,  Tunisia,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN.	Number of participants with Adverse Events following dosing of OMS906.	48 weeks
Secondary	Change in proteinuria measured by 24-hour urine protein/creatinine ratio (UPCR).	Change from baseline in proteinuria measured as 24-hour UPCR at 12, 24, and 48 weeks.	12, 24, 48 weeks
Secondary	Change in proteinuria measured by 24-hour urine protein excretion (UPE).	Change from baseline in proteinuria measured as 24-hour UPE at 12, 24, and 48 weeks.	12, 24, and 48 weeks.
Secondary	Change in proteinuria measured as 24-hour urine albumin excretion (UAE).	Change from baseline in proteinuria measured as 24-hour UAE at 12, 24, and 48 weeks.	Time Frame: 12, 24, and 48 weeks.
Secondary	Change in proteinuria measured as 24-hour urine albumin/creatinine ratio (UACR).	Change from baseline in proteinuria measured as 24-hour UACR at 12, 24, and 48 weeks.	12, 24, and 48 weeks.
Secondary	Incidence of participants with a change from baseline of estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at 24 and 48 weeks.	Number and % of participants with a change from baseline of estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at 24 and 48 weeks.	24 and 48 weeks
Secondary	Incidence of participants with a change from baseline serum creatinine concentration at 24 and 48 weeks.	Number and % of participants with a change from baseline serum creatinine concentration at 24 and 48 weeks.	24 and 48 weeks
Secondary	Pharmacodynamics (PD) of multiple-dose administration of OMS906.	Mature Complement Factor D (CFD) concentration.	48 weeks
Secondary	Pharmacokinetics (PK) of multiple-dose administration of OMS906 - Cmax.	PK parameters including OMS906 maximum concentration - peak plasma concentration (Cmax).	48 weeks
Secondary	Pharmacokinetics (PK) of multiple-dose administration of OMS906 - AUC.	PK parameters - Area under the plasma concentration vs time curve (AUC).	48 weeks
Secondary	OMS906 anti-drug antibodies (ADA).	Number of patients with measurable ADA.	48 weeks